NASDAQ:NVLN Novelion Therapeutics (NVLN) Stock Price, News & Analysis → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free NVLN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.68▼$0.7052-Week Range N/AVolume26,947 shsAverage Volume190,529 shsMarket Capitalization$13.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Novelion Therapeutics Stock (NASDAQ:NVLN)Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Read More Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. NVLN Stock News HeadlinesJune 2, 2023 | finance.yahoo.comCYTO - Altamira Therapeutics Ltd.See More Headlines Company Calendar Last Earnings3/14/2019Today5/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NVLN CUSIPN/A CIK827809 Webwww.novelion.com Phone617-500-7867FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,330,000.00 Net Margins-79.43% Pretax MarginN/A Return on EquityN/A Return on Assets-26.13% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.21 Sales & Book Value Annual Sales$130.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($4.69) per share Price / BookN/AMiscellaneous Outstanding Shares19,619,000Free FloatN/AMarket Cap$13.77 million OptionableOptionable Beta2.12 Key ExecutivesMr. Benjamin S. Harshbarger (Age 50)Interim CEO, Gen. Counsel & Corp. Sec. Mr. Michael D. Price (Age 61)Exec. VP & CFO Mr. Roger W. Louis (Age 63)Global Chief Compliance Officer and Head of R&D Ms. Barbara Y. Chan (Age 55)VP & Chief Accounting Officer Ms. Amanda MurphyDirector of Investor Relations & Corp. CommunicationsKey CompetitorsPieris PharmaceuticalsNASDAQ:PIRSFSD PharmaNASDAQ:HUGERedHill BiopharmaNASDAQ:RDHLEdesa BiotechNASDAQ:EDSAPurple BiotechNASDAQ:PPBTView All Competitors NVLN Stock Analysis - Frequently Asked Questions How were Novelion Therapeutics' earnings last quarter? Novelion Therapeutics Inc. (NASDAQ:NVLN) posted its earnings results on Thursday, March, 14th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to analyst estimates of $40.90 million. What other stocks do shareholders of Novelion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ), Amicus Therapeutics (FOLD), Applied Genetic Technologies (AGTC), Advanced Micro Devices (AMD), Biocept (BIOC), Karyopharm Therapeutics (KPTI), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and Actinium Pharmaceuticals (ATNM). This page (NASDAQ:NVLN) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.